Abstract Number: PB1135
Meeting: ISTH 2021 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: Allogeneic hematopoietic stem cell transplantation (AHSCT) is an established therapy in the treatment of hematological malignancies. In recent years, different studies have reported thromboembolic complications with increased morbidity and bleeding complications with higher mortality in patients undergoing AHSCT.
Aims: To analyze the thrombotic and hemorrhagic complications in patients undergoing AHSCT.
Methods: All patients who underwent a related donor AHSCT between 2010 and 2019 at the Miguel Servet University Hospital (Zaragoza, Spain) were included. Data related to the patient, the hematological disease, AHSCT and follow-up were collected through clinical and laboratory data. The results are expressed in percentages for qualitative variables, and in means, standard deviation (SD) for continuous variables. IBM SPSS Statistics® 20 program was used for their analysis.
Results: 87 patients, 53 men, were included for the study. The mean age at AHSCT was 48.5 years (SD 12.8). The average follow-up was 30 months (SD 31.1). 15 patients had a thrombosis after AHSCT, 12 were deep vein thrombosis (DVT), 6 of which were associated with a central venous catheter (CVC). The mean time from AHSCT to diagnosis of thrombosis was 18 months (SD 20.2). The most commonly used treatment for thrombosis was anticoagulation with low molecular weight heparin (n = 10). Post-AHSCT bleeding complications were detected in 41 patients, mainly gastrointestinal (n = 14) and genitourinary (n = 13). 7 patients had graft-versus-host disease, 6 had BK virus cystitis, and 6 had thrombocytopenia at the time of bleeding. The mean time from AHSCT to detection of bleeding was 9 months (SD 16.9).
Conclusions: The incidence of thrombotic and hemorrhagic complications is similar to that previously published. Most were diagnosed months after AHSCT. The main thrombotic complications were DVT, mostly in patients with a CVC. The hemorrhagic complications were more frequent, located mostly at the digestive and genitourinary level.
To cite this abstract in AMA style:
Gonzalez Gomez E, Fernandez Mosteirin N, Moreno Carbonell M, Pinzon Mariño SF, Garcia Ortego A, Gomez Martinez A, Hernandez Mata CF, Martin Consuegra S, Civeira Marin M, Lopez Peña A, Rodriguez Lefler C, Ordas Miguelez MS, Herrero Gutierrez MdM, Lopez Gomez PE, Delgado Beltran MP, Calvo Villas JM. Thrombotic and Hemorrhagic Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/thrombotic-and-hemorrhagic-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation/. Accessed November 29, 2023.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/thrombotic-and-hemorrhagic-complications-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation/